title: Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor.
abstract: von Willebrand disease (VWD) is a bleeding disorder caused by inherited defects in the concentration, structure, or function of von Willebrand factor (VWF). VWD is classified into three primary categories. Type 1 includes partial quantitative deficiency, type 2 includes qualitative defects, and type 3 includes virtually complete deficiency of VWF. VWD type 2 is divided into four secondary categories. Type 2A includes variants with decreased platelet adhesion caused by selective deficiency of high-molecular-weight VWF multimers. Type 2B includes variants with increased affinity for platelet glycoprotein Ib. Type 2M includes variants with markedly defective platelet adhesion despite a relatively normal size distribution of VWF multimers. Type 2N includes variants with markedly decreased affinity for factor VIII. These six categories of VWD correlate with important clinical features and therapeutic requirements. Some VWF gene mutations, alone or in combination, have complex effects and give rise to mixed VWD phenotypes. Certain VWD types, especially type 1 and type 2A, encompass several pathophysiologic mechanisms that sometimes can be distinguished by appropriate laboratory studies. The clinical significance of this heterogeneity is under investigation, which may support further subdivision of VWD type 1 or type 2A in the future.
authors.affiliation: Howard Hughes Medical Institute, Washington University, St Louis, MO 63110, USA. esadler@im.wustl.edu
authors.forename: J E
authors.initials: JE
authors.lastname: Sadler
authors.forename: U
authors.initials: U
authors.lastname: Budde
authors.forename: J C J
authors.initials: JC
authors.lastname: Eikenboom
authors.forename: E J
authors.initials: EJ
authors.lastname: Favaloro
authors.forename: F G H
authors.initials: FG
authors.lastname: Hill
authors.forename: L
authors.initials: L
authors.lastname: Holmberg
authors.forename: J
authors.initials: J
authors.lastname: Ingerslev
authors.forename: C A
authors.initials: CA
authors.lastname: Lee
authors.forename: D
authors.initials: D
authors.lastname: Lillicrap
authors.forename: P M
authors.initials: PM
authors.lastname: Mannucci
authors.forename: C
authors.initials: C
authors.lastname: Mazurier
authors.forename: D
authors.initials: D
authors.lastname: Meyer
authors.forename: W L
authors.initials: WL
authors.lastname: Nichols
authors.forename: M
authors.initials: M
authors.lastname: Nishino
authors.forename: I R
authors.initials: IR
authors.lastname: Peake
authors.forename: F
authors.initials: F
authors.lastname: Rodeghiero
authors.forename: R
authors.initials: R
authors.lastname: Schneppenheim
authors.forename: Z M
authors.initials: ZM
authors.lastname: Ruggeri
authors.forename: A
authors.initials: A
authors.lastname: Srivastava
authors.forename: R R
authors.initials: RR
authors.lastname: Montgomery
authors.forename: A B
authors.initials: AB
authors.lastname: Federici
mesh_terms: D051722:ADAM Proteins / Q000502:physiology; D000071120:ADAMTS13 Protein; D006801:Humans; D008954:Models, Biological; D010641:Phenotype; D017434:Protein Structure, Tertiary; D014842:von Willebrand Diseases / Q000097:blood* / Q000145:classification / Q000175:diagnosis / Q000503:physiopathology*; D014841:von Willebrand Factor / Q000378:metabolism
chemical_list: D014841:von Willebrand Factor; D051722:ADAM Proteins; D000071120:ADAMTS13 Protein; C099604:ADAMTS13 protein, human